Results of IDA-FLAG programme in the treatment of recurrent acute myeloblastic leukaemia--preliminary report.
Włodzimierz Łuczyński, Katarzyna Muszyńska-Rosłan, Maryna Krawczuk-Rybak, Marta Kuźmicz, Anna Iwaszkiewicz-Pawłowska, Jacek Kaliszewski
Med Sci Monit 2001; 7(1): CR125-129
BACKGROUND: Unsatisfactory treatment results of acute myeloblastic leukaemiainspire the search for new drugs, characterised by higher efficiency and lower toxicity. The aim of thestudy was the assessment of the efficiency and side effects associated with the implementation of IDA-FLAGprotocol.
MATERIAL AND METHODS: The assessment of treatment results and undesirable effects was basedon the material of 4 children with the relapse of acute myeloblastic leukaemia, after a total of 6 IDA-FLAGprotocols.
RESULTS: Complete remission was obtained in 2 (50%) children, with mean remission time of13.5 months. One of the children underwent the transplantation of haematopoietic cells from unrelateddonor. The main side effect observed was bone marrow aplasia. Leucopenia, granulocytopenia, thrombocytopeniaand anaemia persisted for approx. 20 days. Apart from haematological symptoms, the following were alsoobserved: the symptoms of intolerance after ARA-C, aspergillosis of paranasal sinuses and lungs and severecoagulation disorders.
CONCLUSION: IDA-FLAG protocol may be recommended for use in children with AMLrelapse and the undesirable effects observed are acceptable.
Keywords: acute myeloblastic leukaemia, children, fludarabine, IDA-FLAG